COVID-19: French Reimbursement No For MSD’s Lagevrio But Yes For AZ’s Evusheld
Executive Summary
The European Medicines Agency’s advice that Lagevrio could be considered for emergency use still stands despite new data.
You may also be interested in...
Coronavirus Notebook: 35 Generic Firms To Produce Pfizer’s Paxlovid, AZ’s Evusheld Gains UK & Australian Approval
Finland’s Rokote expects to begin clinical trials with its intranasal vaccine after the summer, while Australia’s ENA Respiratory has dosed the first patients in a Phase IIa study of its antiviral nasal spray.
AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds
During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.
UK Nod For Pfizer’s COVID-19 Oral Treatment
Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.